NCT00574210 - PK/PD and Steady State Efficacy Study of Bilastine Compared With Placebo Given Orally in the Treatment of the Symptoms of SAR in an EEC Model (5-arm) | Biotech Hunter

Enrollment

502

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

February 29, 2008

Study Completion Date

February 29, 2008

Conditions

Seasonal Allergic RhinitisHay FeverRhinoconjunctivitis

Interventions

DRUG

Bilastine

Bilastine Tablets, administered at a dosage strength of 10 mg or 20 mg, once or twice per day.

DRUG

Placebo

Placebo Tablets administered twice per day

Trial Locations (1)

Allied Research International - Cetero Research, Mississauga